Oncogenic Ras leads to Rho activation by activating the mitogen-activated protein kinase pathway and decreasing Rho-GTPase-activating protein activity.
about
Non-muscle myosin II in disease: mechanisms and therapeutic opportunitiesWhat links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentThe RHO-1 RhoGTPase modulates fertility and multiple behaviors in adult C. elegansInhibition of MLC phosphorylation restricts replication of influenza virus--a mechanism of action for anti-influenza agentsExtracellular signal-regulated kinase promotes Rho-dependent focal adhesion formation by suppressing p190A RhoGAP.Oncogenic H-Ras V12 promotes anchorage-independent cytokinesis in human fibroblastsp120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line.Bioluminescence resonance energy transfer identify scaffold protein CNK1 interactions in intact cells.R-Ras controls membrane protrusion and cell migration through the spatial regulation of Rac and RhoOncogenic ras-induced down-regulation of autophagy mediator Beclin-1 is required for malignant transformation of intestinal epithelial cellsPrevention of carcinogenesis and inhibition of breast cancer tumor burden by dietary stearate.Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration.Signaling by small GTPases in the immune system.Localization and translocation of RhoA protein in the human gastric cancer cell line SGC-7901.Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides.The extracellular matrix modulates the hallmarks of cancer.GEF-H1 mediates tumor necrosis factor-alpha-induced Rho activation and myosin phosphorylation: role in the regulation of tubular paracellular permeability.Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors.Rho A participates in the regulation of phosphatidylserine-dependent procoagulant activity at the surface of megakaryocytic cells.An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.Coordination of Rho and Rac GTPase function via p190B RhoGAP.RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription.Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway.Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.Regulation of cGMP-dependent protein kinase expression by Rho and Kruppel-like transcription factor-4.Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.Two coffins and a funeral: early or late caspase activation determines two types of apoptosis induced by DNA damaging agents.Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models.
P2860
Q26778962-0771756C-CBA1-458D-99C1-5E88F3207127Q26782585-638D3C74-0DFC-485E-8DE0-47440755695BQ27350466-B5F1143C-E484-4686-8CA8-C262BBD5A6D8Q28478705-C4EA8B71-D117-4421-A275-EA27E28CDEF9Q30433710-DEE1AD8A-BBDF-447E-837E-5AF183858D9FQ30480911-0EE32668-AAEE-4E5E-9750-EECEA84F298DQ31148783-07CE1A31-7AA3-431A-9C5F-AE16E6B6ECD8Q33292257-55F9A512-DA8B-4B2A-980F-BADD52E41A29Q33564310-8949CB6E-B2B7-4984-9D31-43F6D616AFA7Q33648384-195CE611-BB8D-4AA0-84D6-9F39FD4C6D3EQ35144515-DC8A9DE0-F6C3-479E-8FD8-7892A8B6EE98Q36368354-0B4D6AE2-4A13-4017-8E88-5F892D1FEE47Q36877306-B7505770-CF47-4E48-A6EB-D4339CA77AB0Q37212922-96C324B6-A329-43A8-A723-5C3B400C78E9Q37447885-74603799-EE36-489C-9121-DB63035ECE20Q38266276-A86010F0-B30F-4123-9CEE-EA9348D6EFE7Q39877230-17C9CD9D-5F76-48C6-B663-4F8CA91F92A0Q40071304-F5BD27E1-0643-481B-B0FF-D4FB243DA3A1Q40564164-F343049B-F1BD-4601-A1C9-48E022D9C693Q42315790-32EBCEB2-1DB1-491E-A022-117C7D913A5FQ42723117-30521BD8-3977-4365-95C1-3D50BD24505CQ42829566-045AA833-FEC8-427C-B455-C2D8A3FCA3DAQ42834991-FCD80266-478B-4DC6-9DEE-7A5590FF4403Q45057128-5D3D35DE-0438-4C60-92D0-4BE5CF81ED79Q46359946-5336A323-FA4C-46FA-AB73-1596C24E967DQ48212640-869706F9-513B-4352-8CBB-249C6C8330BEQ50221540-E48CA6E5-E953-45DC-AC58-5FA1216652E9Q50736424-3E421E49-4CA0-4B1D-AC0C-F27593734E5B
P2860
Oncogenic Ras leads to Rho activation by activating the mitogen-activated protein kinase pathway and decreasing Rho-GTPase-activating protein activity.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Oncogenic Ras leads to Rho act ...... e-activating protein activity.
@en
Oncogenic Ras leads to Rho act ...... e-activating protein activity.
@nl
type
label
Oncogenic Ras leads to Rho act ...... e-activating protein activity.
@en
Oncogenic Ras leads to Rho act ...... e-activating protein activity.
@nl
prefLabel
Oncogenic Ras leads to Rho act ...... e-activating protein activity.
@en
Oncogenic Ras leads to Rho act ...... e-activating protein activity.
@nl
P2093
P2860
P356
P1476
Oncogenic Ras leads to Rho act ...... e-activating protein activity.
@en
P2093
Gerry R Boss
Jeffrey C Chen
Renate B Pilz
Shunhui Zhuang
Tony H Nguyen
P2860
P304
P356
10.1074/JBC.M207943200
P407
P577
2002-11-11T00:00:00Z